Mamta Jain, MD
Infectious Disease · Dallas, TXNPI 1114989290
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $10,654 of the $13,464 with a category attached, or 79.1%. Gilead accounts for 97.2% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2019 at $11,067 and has fallen 98.7% since, to $141 in 2025. Among infectious disease clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 39 payments — averaging $345.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$13K
- Kestra Medical Technology Services, Inc.$179
- Viiv Healthcare Company$111
- Merck$39
- Bayer$30
- GSK$15
Across 207 payments — averaging $17,576 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Gilead$2.9M
- Regeneron$409K
- AbbVie$109K
- Merck$65K
- Janssen Research & Development, LLC$63K
- Viiv Healthcare Company$56K
- plus $37K from 2 others
What the payments were for
- Consulting fees$10,65479%
- Travel & lodging$1,95715%
- Food & beverage$8536%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 29 | $13,091 |
| Kestra Medical Technology Services, Inc. | 6 | $179 |
| Viiv Healthcare Company | 1 | $111 |
| Merck | 1 | $39 |
| Bayer | 1 | $30 |
| GSK | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DOVATO$111
How this compares
$13,464 in reported general payments places this provider in the 90th percentile of 576 infectious disease providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 37 | $174,153 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 44 | $165,470 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 26 | $102,249 |
| TivicayDolutegravir Sodium | 43 | $95,107 |
| PrezcobixDarunavir/Cobicistat | 24 | $58,623 |
| JulucaDolutegravir/Rilpivirine | 12 | $42,367 |
| DescovyEmtricitabine/Tenofov Alafenam | 19 | $41,169 |
| Darunavir | 24 | $39,202 |
| DovatoDolutegravir Sodium/Lamivudine | 12 | $37,006 |
| JardianceEmpagliflozin | 19 | $21,057 |
| TrulicityDulaglutide | 13 | $11,348 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 13 | $7,600 |
| Novolog FlexpenInsulin Aspart | 11 | $4,258 |
| Ritonavir | 15 | $2,645 |
| Atorvastatin Calcium | 57 | $589 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Viiv Healthcare CompanyTriumeq, Tivicay, Juluca, Dovato | $111 | $339,949111 claims |
| GileadBiktarvy, Descovy | $13,091 | $143,41845 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 576 infectious disease providers in Texas.
Other infectious disease in Dallas
- Elizabeth RaceDallas$1.5M
- Uriel SandkovskyDallas$320K
- Roger BedimoDallas$269K
- Edward DominguezDallas$121K
- Robert HardyDallas$116K
- Mezgebe BerheDallas$66K
- Ank NijhawanDallas$39K
- Philip KeiserDallas$38K
- Helen KingDallas$37K
- Jason GillmanDallas$24K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.